Key facts
- AbbVie is nearing a deal to acquire Apogee Therapeutics.
- The acquisition is valued at approximately $10.9 billion in cash.
- The deal aims to bolster AbbVie's immunology pipeline.
- Apogee Therapeutics' lead drug candidate is zumilokibart.
- Zumilokibart is an experimental treatment for inflammatory diseases.
AbbVie is nearing an agreement to acquire Apogee Therapeutics for an estimated $10.9 billion in cash. The primary objective of this acquisition is to strengthen AbbVie's immunology pipeline. Apogee Therapeutics' lead drug candidate, zumilokibart, is central to this strategy. Zumilokibart is an experimental treatment currently under development for inflammatory diseases. The acquisition is expected to significantly bolster AbbVie's offerings in the immunology sector by integrating this promising new therapy into its existing portfolio. This move signals AbbVie's continued investment in expanding its presence and capabilities within the immunology market, aiming to address unmet patient needs in inflammatory conditions with novel therapeutic options.